AngioDynamics CFO sells 25,335 shares

AngioDynamics Inc. EVP and CFO Stephen A. Trowbridge reported two direct Common Stock sales: 1,720 shares on October 28, 2026, at a weighted-average price of $12.17 per share, and 23,615 shares on October 29, 2026, at $12.27 per share.

Available on EDGAR 10/30/2026 - 04:15 PM EDT Accepted by SEC EDGAR 10/30/2026 - 04:15 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

AngioDynamics Inc. EVP and CFO Stephen A. Trowbridge reported two direct Common Stock sales: 1,720 shares on October 28, 2026, at a weighted-average price of $12.17 per share, and 23,615 shares on October 29, 2026, at $12.27 per share. Associated footnotes describe multiple transactions, with respective price ranges of $12.15–$12.20 and $12.07–$12.35. No Rule 10b5-1 plan is reported.

Insider Trade Summary

Net Seller: 25,335 shares

Net Sell 2 txns

Insider Trowbridge Stephen A

Role EVP and CFO

Sold 25,335 shs ($311K)

Type	Security	Shares	Price	Value
Sale	Common Stock F2	23,615	$12.27	$290K
Sale	Common Stock F1	1,720	$12.17	$21K

Holdings After Transaction: Common Stock — 280,461 shares (Direct)

Footnotes (2)

1. F1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.15 to $12.20, inclusive. The reporting person has provided to AngioDynamics, Inc., and undertakes to provide to any security holder of AngioDynamics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote 1.
2. F2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.07 to $12.35 inclusive. The reporting person has provided to AngioDynamics, Inc., and undertakes to provide to any security holder of AngioDynamics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote 2.

Key Figures

Shares sold: 1,720 shares Weighted-average price: $12.17 per share Transaction price range: $12.15–$12.20 +4 more

7 metrics

Shares sold 1,720 shares October 28, 2026

Weighted-average price $12.17 per share October 28, 2026

Transaction price range $12.15–$12.20 Multiple transactions associated with the October 28, 2026 sale

Shares sold 23,615 shares October 29, 2026

Weighted-average price $12.27 per share October 29, 2026

Transaction price range $12.07–$12.35 Multiple transactions associated with the October 29, 2026 sale

Shares sold across reported transactions 25,335 shares Two reported sales

Key Terms

weighted average price, open market or private transaction, non-derivative

3 terms

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open market or private transaction financial

"Sale in open market or private transaction"

non-derivative technical

"transaction_type: non-derivative"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did ANGO EVP and CFO Stephen A. Trowbridge sell?

Stephen A. Trowbridge reported selling 1,720 shares on October 28, 2026, at a weighted-average $12.17 per share and 23,615 shares on October 29, 2026, at $12.27 per share. The associated footnotes give respective price ranges of $12.15–$12.20 and $12.07–$12.35; no Rule 10b5-1 plan is reported.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Trowbridge Stephen A

(Last) (First) (Middle)

14 PLAZA DRIVE

(Street)

LATHAM NEW YORK 12110

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ANGIODYNAMICS INC [ ANGO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP and CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/28/2026		S		1,720	D	$12.17(1)	304,076	D
Common Stock	10/29/2026		S		23,615	D	$12.27(2)	280,461	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.15 to $12.20, inclusive. The reporting person has provided to AngioDynamics, Inc., and undertakes to provide to any security holder of AngioDynamics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote 1.

2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.07 to $12.35 inclusive. The reporting person has provided to AngioDynamics, Inc., and undertakes to provide to any security holder of AngioDynamics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote 2.

	/s/ Lawrence T. Weiss, as Attorney in Fact	10/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)